Table 1.
Characteristics of included studies.
| Study ID | Year | Region | Ages | Sample size | Regimens of treatment group | Regimens of control group | Outcomes | |
|---|---|---|---|---|---|---|---|---|
| Combination group | SC group | |||||||
| Chang et al. | 1987 | America | 57 (37–77) | 61 (37–70) | 64 | HAIC: FUDR | SC: FUDR | OS, RRs |
| Kemeny et al. | 1987 | America | 60 (36–76) | 61 (37–75) | 99 | HAIC: FUDR | SC: FUDR | OS, RRs |
| Hohn et al. | 1989 | America | 61.2 (34–79) | 61.8 (36–79) | 115 | HAIC: FUDR | SC: FUDR | OS, RRs |
| Martin et al. | 1990 | America | NR | NR | 69 | HAIC: FUDR | SC: 5-FU | OS, RRs, PFS |
| Wagman et al. | 1990 | America | 57.8 (37–73) | 67 (54–76) | 41 | HAIC: FUDR | SC: 5-FU | OS, RRs |
| Rougier et al. | 1992 | France | 59 ± 8 | 61 ± 10 | 163 | HAIC: FUDR | SC: 5-FU/BSC | OS, RRs |
| Allen-Mersh et al. | 1994 | England | 55 ± 10 | 59 ± 8 | 100 | HAIC: FUDR | SC: 5-FU/BSC | OS |
| Kemeny et al. | 1999 | America | 59 (28–79) | 59 (30–77) | 156 | HAIC: FUDR+DXM+LV+5-FU | SC: LV+5-FU | OS, PFS |
| Kusunoki et al. | 2000 | Japan | 60.0 (25–71) | 55.5 (33–75) | 58 | HAIC: 5-FU+UFT | SC: UFT | OS |
| Lorenz et al. | 2000 | Germany | 60.5 (33–78) | 62 (37–80) | 168 | HAIC: FUDR/5-FU+LV | SC: 5-FU/LV | OS, RRs, PFS |
| Tono et al. | 2000 | Japan | 59.0 ± 5.8 | 61.9 ± 5.0 | 19 | HAIC: 5-FU | SC: 5-FU | OS |
| Kerr et al. | 2003 | England | 63 | 62 | 290 | HAIC: 5-FU+LV | SC: 5-FU+LV | OS, RRs, PFS |
| Kemeny et al. | 2006 | America | 57 (21–81) | 61 (35–86) | 135 | HAIC: FUDR | SC: 5-FU+LV | OS, RRs, PFS |
| Fiorentini et al. | 2012 | Italy | 64 (44–74) | 63 (42–73) | 74 | HAIC: CPT-11 | SC: CPT-11+5-FU+LV | OS, RRs, PFS |
| Li et al. | 2016 | China | 78 (75–80) | 77.5 (75–82) | 51 | HAIC: FUDR+CAP | SC: CAP | RRs |
| Kusano et al. | 2017 | Japan | 63.0 (40–80) | 62.5 (46–80) | 88 | HAIC:5-FU | SC: 5-FU | OS |
| Kusano et al. | 2018 | Japan | 62.4 (45–78) | 64.2 (32–77) | 44 | HAIC: 5-FU+LV+UFT | SC: LV+UFT | OS |
| Ghiringhelli et al. | 2019 | France | 65.6(44.5–82.4) | 54.7 (39.9–81.9) | 27 | HAIC: raltitrexed+OXA | SC: AP/MMC/regorafenib | OS, PFS |
HAIC, hepatic arterial infusion chemotherapy; SC, systemic chemotherapy; 5-Fu, fluorouracil; FUDR, floxuridine; LV, leucovorin; UFT, uracil tegafur; OXA, oxaliplatin; CAP, capecitabine; MMC, mitomycin C; CPT-11, irinotecan; DXM, dexamethasone; BSC, best supportive care; NR, not reported.